Relationship between Sfrp5 and T2DM macroangiopathy and activation of calcium dobesilate
10.3969/j.issn.1006-5725.2016.18.028
- VernacularTitle:分泌型卷曲相关蛋白5与2型糖尿病大血管病变的相关性及羟苯磺酸钙的干预性研究
- Author:
Lanfang LI
;
Jiaoe ZENG
- Publication Type:Journal Article
- Keywords:
T2DM macroangiopathy;
Sfrp5;
IL-10;
Calcium dobesilate
- From:
The Journal of Practical Medicine
2016;32(18):3044-3046
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relationship between Sfrp5 and T2DM macroangiopathy , and to evaluate the activation of calcium dobesilate. Methods T2DM patients were divided into experimental group (IMT≥0.90 mm,n = 65)and control group (IMT < 0.90 mm, n = 30)and patients in experimental group were randomly further divided into group A (n = 30,treated with calcium dobesilate) and group B (n = 35, treated with routine therapy). Another 20 healthy control were involved as normal group. Sfrp5,IL-10,TC,TG,FPG, HbA1c and IMT were observed before and after treatment. Results Sfrp5 and IL-10 in experimental group and control group were lower than those in normal group (P < 0.01)and Sfrp5 and IL-10 in experimental group were lower than those in control group (P < 0.05). Correlation analysis showed that sfrp5 and IL-10 were negatively correlated with these above-mentioned indicators and Sfrp5 was positively correlated with IL-10(P < 0.05). After 16-week treatment, the contents of FBG, lipid, HbA1c and IMT were decreased in group A and B, but Sfrp5 and IL-10 were increased in group A (P < 0.01). Sfrp5 and IL-10 didn't alter significantly in group B (P >0.05). IMT in group A were decreased when compared with group B (P < 0.05). Conclusion Sfrp5 is negatively correlated with macroangiopathy. Calcium dobesilate can elevate Sfrp5 and IL-10,thus delay the progression of macroangiopathy.
